Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | MGAM | O43451 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18170240 | 0.85 | MGAM (0.37) | MGAMGAAGBA1 | |
| SCHEMBL18170178 | 0.83 | SMYD2 (0.36) | MGAMSMYD2 | |
| SCHEMBL31409894 | 0.81 | MGAM (0.38) | DRD2DRD3MGAMSMYD2GAA | |
| SCHEMBL15877751 | 0.81 | MGAM (0.38) | DRD2DRD3MGAMSMYD2GAA | |
| SCHEMBL17894245 | 0.81 | MGAM (0.38) | DRD2DRD3MGAMSMYD2GAA | |
| SCHEMBL18170213 | 0.76 | SMYD2 (0.34) | SMYD2 | |
| SCHEMBL16369034 | 0.75 | MAPT (0.43) | MGAMMAPTSMYD2GAASIGMAR1 | |
| SCHEMBL16368996 | 0.75 | MAPT (0.43) | MGAMMAPTSMYD2GAASIGMAR1 | |
| SCHEMBL31372572 | 0.75 | MGAM (0.37) | MGAMMAPTSMYD2GAASIGMAR1 | |
| SCHEMBL31372503 | 0.75 | MGAM (0.37) | MGAMMAPTSMYD2GAASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834526-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160311786-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311786-A1 | HIV PROTEASE INHIBITORS | PREP, PRSS1, CTSV | DRD2 2420/4885DRD3 2146/4885MGAM 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.